OUTLOOK THERAPEUTICS, INC. Research and Development Expense
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Research and Development Expense of $3.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $3.25M, a 54.43% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $4.50M, a 2.12% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $3.63M, a 62.38% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $5.98M, a 52.26% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. research and development expense for fiscal 2025 was $27.18M, a 34.92% decline from fiscal 2024.
- OUTLOOK THERAPEUTICS, INC. research and development expense for fiscal 2024 was $41.76M, a 57.88% increase from fiscal 2023.
- OUTLOOK THERAPEUTICS, INC. research and development expense for fiscal 2023 was $26.45M, a 37.51% decline from fiscal 2022.
- OUTLOOK THERAPEUTICS, INC. research and development expense for fiscal 2022 was $42.33M, a 8.66% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.25M 10-Q · filed 2026-08-18 | $7.75M derived: sum of 2 quarters · filed 2026-08-18 | $11.39M 10-Q · filed 2026-08-18 | $17.36M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2026-03-31 | $4.50M 10-Q · filed 2026-05-15 | $8.13M 10-Q · filed 2026-05-15 | $14.11M derived: sum of 3 quarters · filed 2026-05-15 | $21.25M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2025-12-31 | $3.63M 10-Q · filed 2026-02-17 | $9.61M derived: sum of 2 quarters · filed 2026-02-17 | $16.75M derived: sum of 3 quarters · filed 2026-08-18 | $21.15M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2025-09-30 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $13.11M derived: sum of 2 quarters · filed 2026-08-18 | $17.52M derived: sum of 3 quarters · filed 2026-08-18 | $27.18M 10-K · filed 2025-12-19 | ||||
| 2025-06-30 | $7.13M 10-Q · filed 2026-08-18 | $11.54M derived: sum of 2 quarters · filed 2026-08-18 | $21.20M 10-Q · filed 2026-08-18 | $33.72M derived: sum of 4 quarters · filed 2026-08-18 | ||||
| 2025-03-31 | $4.41M 10-Q · filed 2026-05-15 | $14.07M 10-Q · filed 2026-05-15 | $26.59M derived: sum of 3 quarters · filed 2026-05-15 | $37.79M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $9.66M 10-Q · filed 2026-02-17 | $22.18M derived: sum of 2 quarters · filed 2026-02-17 | $33.38M derived: sum of 3 quarters · filed 2026-02-17 | $46.89M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2024-09-30 | $12.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $23.72M derived: sum of 2 quarters · filed 2025-12-19 | $37.23M derived: sum of 3 quarters · filed 2025-12-19 | $41.76M 10-K · filed 2025-12-19 | ||||
| 2024-06-30 | $11.20M 10-Q · filed 2025-08-14 | $24.71M derived: sum of 2 quarters · filed 2025-08-14 | $29.24M 10-Q · filed 2025-08-14 | $34.18M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $13.51M 10-Q · filed 2025-05-15 | $18.04M 10-Q · filed 2025-05-15 | $22.98M derived: sum of 3 quarters · filed 2025-05-15 | $34.08M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $4.53M 10-Q · filed 2025-02-14 | $9.47M derived: sum of 2 quarters · filed 2025-02-14 | $20.57M derived: sum of 3 quarters · filed 2025-02-14 | $21.12M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-09-30 | $4.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $16.05M derived: sum of 2 quarters · filed 2024-12-27 | $16.59M derived: sum of 3 quarters · filed 2024-12-27 | $26.45M 10-K · filed 2024-12-27 | ||||
| 2023-06-30 | $11.10M 10-Q · filed 2024-08-14 | $11.65M derived: sum of 2 quarters · filed 2024-08-14 | $21.51M 10-Q · filed 2024-08-14 | $30.50M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $544.95K 10-Q · filed 2024-05-15 | $10.41M 10-Q · filed 2024-05-15 | $19.40M derived: sum of 3 quarters · filed 2024-05-15 | $30.65M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $9.86M 10-Q · filed 2024-02-14 | $18.85M derived: sum of 2 quarters · filed 2024-02-14 | $30.10M derived: sum of 3 quarters · filed 2024-02-14 | $42.32M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-09-30 | $8.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-22 | $20.24M derived: sum of 2 quarters · filed 2023-12-22 | $32.46M derived: sum of 3 quarters · filed 2023-12-22 | $42.33M 10-K · filed 2023-12-22 | ||||
| 2022-06-30 | $11.25M 10-Q · filed 2023-08-14 | $23.47M derived: sum of 2 quarters · filed 2023-08-14 | $33.34M 10-Q · filed 2023-08-14 | $43.28M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $12.22M 10-Q · filed 2023-05-15 | $22.09M 10-Q · filed 2023-05-15 | $32.03M derived: sum of 3 quarters · filed 2023-05-15 | $40.57M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $9.87M 10-Q · filed 2023-02-14 | $19.81M derived: sum of 2 quarters · filed 2023-02-14 | $28.35M derived: sum of 3 quarters · filed 2023-02-14 | $36.88M derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-09-30 | $9.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-29 | $18.48M derived: sum of 2 quarters · filed 2022-12-29 | $27.01M derived: sum of 3 quarters · filed 2022-12-29 | $38.96M 10-K · filed 2022-12-29 | ||||
| 2021-06-30 | $8.55M 10-Q · filed 2022-08-10 | $17.07M derived: sum of 2 quarters · filed 2022-08-10 | $29.02M 10-Q · filed 2022-08-10 | $36.65M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $8.53M 10-Q · filed 2022-05-13 | $20.48M 10-Q · filed 2022-05-13 | $28.10M derived: sum of 3 quarters · filed 2022-05-13 | $36.59M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $11.95M 10-Q · filed 2022-02-14 | $19.57M derived: sum of 2 quarters · filed 2022-02-14 | $28.06M derived: sum of 3 quarters · filed 2022-02-14 | $32.44M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-09-30 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | $16.11M derived: sum of 2 quarters · filed 2021-12-23 | $20.49M derived: sum of 3 quarters · filed 2021-12-23 | $26.34M 10-K · filed 2021-12-23 | ||||
| 2020-06-30 | $8.49M 10-Q · filed 2021-08-13 | $12.87M derived: sum of 2 quarters · filed 2021-08-13 | $18.72M 10-Q · filed 2021-08-13 | $26.17M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $4.38M 10-Q · filed 2021-05-14 | $10.23M 10-Q · filed 2021-05-14 | $17.69M derived: sum of 3 quarters · filed 2021-05-14 | $22.03M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $5.85M 10-Q · filed 2021-02-16 | $13.30M derived: sum of 2 quarters · filed 2021-02-16 | $17.65M derived: sum of 3 quarters · filed 2021-02-16 | $23.58M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-09-30 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | $11.80M derived: sum of 2 quarters · filed 2020-12-23 | $17.73M derived: sum of 3 quarters · filed 2020-12-23 | $23.81M 10-K · filed 2020-12-23 | ||||
| 2019-06-30 | $4.34M 10-Q · filed 2020-08-14 | $4.39M 10-Q · filed 2019-08-14 | $10.28M derived: sum of 2 quarters · filed 2020-08-14 | $16.35M 10-Q · filed 2020-08-14 | $19.31M 10-Q · filed 2019-08-14 | $23.50M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $5.94M 10-Q · filed 2020-05-15 | $6.50M 10-Q · filed 2019-05-15 | $12.01M 10-Q · filed 2020-05-15 | $14.92M 10-Q · filed 2019-05-15 | $19.16M derived: sum of 3 quarters · filed 2020-05-15 | $24.95M derived: sum of 4 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $6.07M 10-Q · filed 2020-02-14 | $8.42M 10-Q · filed 2019-02-14 | $13.22M derived: sum of 2 quarters · filed 2020-02-14 | $19.02M derived: sum of 3 quarters · filed 2020-02-14 | $24.17M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-09-30 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | $12.95M derived: sum of 2 quarters · filed 2019-12-19 | $18.10M derived: sum of 3 quarters · filed 2019-12-19 | $18.50M 10-K · filed 2019-12-19 | ||||
| 2018-06-30 | $5.80M 10-Q · filed 2019-08-14 | $10.95M derived: sum of 2 quarters · filed 2019-08-14 | $11.35M 10-Q · filed 2019-08-14 | $13.66M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | $5.16M 10-Q · filed 2019-05-15 | $5.56M 10-Q · filed 2019-05-15 | $7.86M derived: sum of 3 quarters · filed 2019-05-15 | $12.02M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $402.40K 10-Q · filed 2019-02-14 | $2.71M derived: sum of 2 quarters · filed 2019-02-14 | $6.86M derived: sum of 3 quarters · filed 2019-02-14 | $10.98M derived: sum of 4 quarters · filed 2019-02-14 | ||||
| 2017-09-30 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | $6.46M derived: sum of 2 quarters · filed 2018-12-18 | $10.58M derived: sum of 3 quarters · filed 2018-12-18 | $23.81M 10-K · filed 2018-12-18 | ||||
| 2017-06-30 | $4.16M 10-Q · filed 2018-08-14 | $4.24M 10-Q · filed 2017-08-14 | $8.27M derived: sum of 2 quarters · filed 2018-08-14 | $21.50M 10-Q · filed 2018-08-14 | $21.75M 10-Q · filed 2017-08-14 | $25.38M derived: sum of 4 quarters · filed 2018-08-14 | ||
| 2017-03-31 | $4.12M 10-Q · filed 2018-05-15 | $4.20M 10-Q · filed 2017-05-15 | $17.35M 10-Q · filed 2018-05-15 | $17.51M 10-Q · filed 2017-05-15 | $21.22M derived: sum of 3 quarters · filed 2018-05-15 | $33.24M derived: sum of 4 quarters · filed 2018-05-15 | ||
| 2016-12-31 | $13.23M 10-Q · filed 2018-02-14 | $13.31M 10-Q · filed 2017-02-14 | $17.10M derived: sum of 2 quarters · filed 2018-02-14 | $29.12M derived: sum of 3 quarters · filed 2018-02-14 | $33.26M derived: sum of 4 quarters · filed 2018-02-14 | |||
| 2016-09-30 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | $15.89M derived: sum of 2 quarters · filed 2017-12-29 | $20.03M derived: sum of 3 quarters · filed 2017-12-29 | $32.76M 10-K · filed 2017-12-29 | $33.10M 10-K · filed 2016-12-29 | |||
| 2016-06-30 | $12.02M 10-Q · filed 2017-08-14 | $16.16M derived: sum of 2 quarters · filed 2017-08-14 | $28.89M 10-Q · filed 2017-08-14 | $42.09M derived: sum of 4 quarters · filed 2017-08-14 | ||||
| 2016-03-31 | $4.14M 10-Q · filed 2017-05-15 | $16.87M 10-Q · filed 2017-05-15 | $30.07M derived: sum of 3 quarters · filed 2017-05-15 | $39.75M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $12.73M 10-Q · filed 2017-02-14 | $25.93M derived: sum of 2 quarters · filed 2017-02-14 | $35.62M derived: sum of 3 quarters · filed 2017-02-14 | $45.77M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-09-30 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-29 | $22.88M derived: sum of 2 quarters · filed 2016-12-29 | $33.04M derived: sum of 3 quarters · filed 2016-12-29 | $38.88M 10-K · filed 2016-12-29 | ||||
| 2015-06-30 | $9.68M 10-Q · filed 2016-08-15 | $19.84M derived: sum of 2 quarters · filed 2016-08-15 | $25.68M 10-Q · filed 2016-08-15 | |||||
| 2015-03-31 | $10.15M 10-Q · filed 2016-06-27 | $15.99M 10-Q · filed 2016-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |